Learning Clinical-Trial Strategy: Offline Policy Training for Decision Agents
A study frames oncology clinical development as an offline decision-making problem. A temporal dataset of 31.7k public records (trial registries, regulatory reviews, sponsor filings, utilization data, epidemiology) was constructed into 881 offline decision episodes across 45 historical programs. Four offline training objectives (behavioral cloning, reward-weighted behavioral cloning, learned-reward training, value-based implicit Q-learning) were compared against four frontier LLM agents with a date-gated retrieval scaffold. Offline-trained models outperformed non-fine-tuned baselines, especially in post-August 2025 holdout. Reward-weighted behavioral cloning achieved 46.2% indication F1 and 14.2% strict F1.
Researchers frame oncology clinical development as an offline decision-making problem, constructing a dataset of 31.7k public records into 881 decision episodes across 45 historical programs. They compare four offline training objectives against four frontier LLM agents with a date-gated retrieval scaffold. Offline-trained models outperform non-fine-tuned baselines, with reward-weighted behavioral cloning achieving 46.2% indication F1 and 14.2% strict F1, particularly in a post-August 2025 contamination-clean holdout.
The study demonstrates that offline policy training methods, especially reward-weighted behavioral cloning, can effectively learn clinical-trial portfolio decisions from historical data, outperforming frontier LLM agents in a contamination-free temporal split. The use of a date-gated retrieval scaffold ensures realistic evaluation, and the performance gap highlights the value of specialized training over general-purpose LLMs for sequential decision-making under uncertainty.
Pharmaceutical sponsors could leverage offline-trained decision agents to optimize clinical-trial portfolio planning, potentially reducing costly trial failures and accelerating drug development. The approach uses publicly available data, making it accessible for adoption. However, the modest strict F1 score (14.2%) indicates room for improvement before real-world deployment.
Improved clinical-trial strategy can lead to significant cost savings and higher success rates in drug development. An AI agent that accurately predicts optimal trial portfolios could become a valuable tool for pharmaceutical companies, potentially reducing the average $2.6 billion cost of bringing a drug to market.
Next signals include further refinement of reward modeling and incorporation of additional data modalities (e.g., real-world evidence, genomic data) to improve strict F1. Validation on prospective trials and integration with sponsor decision workflows will be critical. Regulatory acceptance of AI-assisted trial design may also evolve.